Binnopharm
Since 2006
Russia
Central Federal District of the Russian Federation
Moscow
4th Western passage, house 3, building 1
Binnopharm Group is a full-cycle pharmaceutical holding that produces generic drugs of various nosologies. The holding was formed in 2020 as a result of the merger of shares in pharmaceutical assets of AFK Sistema.
Aktivs
As of April 2022, the pharmaceutical company Binnopharm Group unites 5 production sites located in different regions of Russia:
- JSC "Alium" (formerly "Obolenskoye" in the Serpukhov district of the Moscow region),
- Binnopharm JSC (2 sites: Zelenograd and Krasnogorsk),
- OAO Sintez (g Barrow.),
- CJSC Biolump"" (g Stavropol.).
It was formed in 2020 as a result of the consolidation of shares in pharmaceutical assets of AFK Sistema.
Product Portfolio
As of April 2022, Binnopharm Group enterprises produce a wide range of drugs of various therapeutic groups in almost all existing dosage forms and have a total of one of the largest portfolios of drugs among Russian manufacturers - more than 450 marketing authorizations.
Performance indicators
2023: Revenue growth by 14% to RUB 32.5 billion
In 2023, Binnopharm Group earned 32.5 billion rubles in net revenue, which is 14% more than a year earlier. Profit during this time decreased from 1.5 billion to 307.3 million rubles. Such data was published by one of the largest drug manufacturers in Russia at the end of March 2024.
The net debt of the pharmaceutical group at the end of 2023 was at the level of 12.7 billion rubles. The net debt/EBITDA ratio is at the target level of 1.3x, Binnopharm Group said in a statement.
In 2023, the group produced 317 million packages of medicines, which exceeds the one-year-old figure. What kind of dynamics are in question is not specified. Sales of drugs produced by Binnopharm Group enterprises in retail in 2023 increased by 29%, while the entire pharmaceutical market of the Russian Federation grew by 4%. The company took fourth place in the list of the largest pharmaceutical manufacturers in retail sales (data from the analytical agency AlphaRM) thanks to the drugs Neobutin, Angiorus, Diclofenac-AKOS (gel), Omeprazol-OBL, Venarus, Maksilak and Lorotricin-ALIUM.
Binnopharm Group's sales abroad in 2023 increased by 11% in packaging, ahead of market growth by more than 5 times (2% in packaging - AlphaRM data are given in the Binnopharm Group press release).
The company's investment in development, including production and the R&D center, reached 4 billion rubles in 2023. Thanks to such investments, Binnopharm Group enterprises are expanding product lines and increasing production of antibacterial, painkillers, antipyretics, venotonics and other drugs, the company added.
 | The company invests a lot in the modernization of production sites and R&D, the development of the drug portfolio and international expansion. We also continue to improve the strategy for promoting focal products, increase research and development, and develop personnel, "said Rustem Muratov, head of the group.[1] |  |
History
2024
Agreement with IPPF on participation in the compensation program for interest payment under the loan agreement
Binnopharm Group signed an agreement with the Moscow Fund for Industry and Entrepreneurship Support to participate in the interest compensation program under a loan agreement concluded by the company with the bank. Additional funds received as a result of participation in the program will be directed to the implementation of a project to create a production of a full cycle of drugs based on monoclonal antibodies (MAB) at the Binnopharm Zelenograd site. The company announced this on November 20, 2024.
The agreement will allow the company to reimburse within three years from the date of signing the agreement the cost of paying interest on the loan in the amount of up to 1 billion rubles. More than 2 billion rubles will be invested in the creation of full-cycle production. It is planned that the first batches of drugs will go into civilian circulation in early 2026.
| | In the current macroeconomic environment, projects to modernize and open new industries require the most careful and balanced approach in terms of payback periods and sources of financing. The IPPFiP compensation program provides comfortable investment conditions for industrial enterprises implementing projects in Moscow to launch new industries. For Binnopharm Group, this means accelerating the process of bringing to market socially significant drugs used for the treatment of cancer and autoimmune diseases. said Hafiz Gafurov , chief financial officer of Binnopharm Group.
| |
Investing 2 billion rubles in production projects in the first half of the year
The Russian pharmaceutical Binnopharm Group in the first half of 2024 invested about 2 billion rubles in its own production projects. The main investments were made in the production sites and R&D the center of the company, representatives of Binnopharm Group said on August 15, 2024.
According to the analytical agency AlphaRM, in the first six months of 2024, Binnopharm Group's growth rate amounted to 26% in the pharmacy segment. Taking into account the increased need of Russian patients for modern medicines, as well as the entry of Binnopharm Group into the Chinese market and the further implementation of the international expansion strategy, the company continues to actively invest in the development of production and innovation.
Among the most priority projects in 2024, Binnopharm Group highlights the expansion of the pharmaceutical enterprise in Zelenograd, which will start the production of extremely popular monoclonal antibody-based drugs (MAB), the construction of a modern warehouse complex at the Synthesis Kurgan, and an increase in the production capacity of the granulation line at the ALIUM site in the Moscow region.
In addition, Binnopharm Group continues to develop its R&D center, launched in 2023 in, Krasnogorsk where work is underway to create a site for the production of highly active drugs (NIS).
| | Binnopharm Group's investment strategy is aimed at increasing production volumes and expanding the range of drugs in demand by foreign and Russian markets. To do this, the company constantly modernizes and automates production processes. In the near future, we expect a significant increase in the company's operating performance thanks to our investment program, "said Hafiz Gafurov, CFO of Binnopharm Group. | |
Investing 16 billion rubles in the development of its R&D center in the Moscow region
The pharmaceutical company Binnopharm Group at the end of May 2024 announced plans to invest 16 billion rubles in the development of its research and development center (R&D center) in the Moscow region. This step is aimed at strengthening the company's position in the field of innovative pharmaceutical development and maintaining high standards of product quality, the group noted.
Earlier in May 2024, the governor Moscow region Andrei Vorobyov visited the Binnopharm Group R&D center in Krasnogorsk, where he got acquainted with the production facilities and analytical laboratories of the center. He highly appreciated the work of the center and noted the importance of such projects for the region and the country as a whole. Vorobyov stressed that the Moscow region has concentrated about a quarter of the total pharmaceutical market Russia, and support for such initiatives is a priority for local authorities.
The Pharmaceutical Development Center in Krasnogorsk, opened in 2023, by the end of May 2024 has about 90 specialists, including analytical chemists and process engineers. His laboratories are engaged in the development of new drugs and the improvement of existing ones. The focus is on the development of anticoagulants, drugs for the treatment of diabetes and cancer, as well as neurological drugs and remedies for women's health.
According to Binnopharm, in 2025 it is planned to open an educational and scientific center in the center together with MIPT, where students and master's students will be trained. There are also plans to create a center for the development of biotechnological drugs, the construction of a specialized school for employees and the development of housing infrastructure.
Alexey Chupin, director of development and registration at Binnopharm Group, said that 40 new drugs aimed at import substitution are being developed in 2024. On the second floor of the research center, equipment is installed for the production of drugs of any toxicity class. The company also actively attracts young professionals, creating its own training center for their training.
The total investment in the creation and development of the Binnopharm Group R&D Center is 2.5 billion rubles, and by 2030 more than 400 qualified specialists will work at the center. This investment is aimed at supporting innovative developments in pharmaceuticals and ensuring high standards of[2] quality[3]
Change of registration to Russian
In February 2024, Binnopharm Group changed its registration from Cypriot to Russian. Two companies through which AFK Sistema owns a pharmaceutical holding received a residence permit in a special administrative district (SAR) of Kaliningrad.
According to the Interfax news agency, citing data from the Unified State Register of Legal Entities (USRUL), on February 8, 2024, Synocom Investments Limited and Ristango Holding Limited were registered on February 8. We are talking about the redomication of two Cypriot companies - Sinocom Investments Limited and Ristango Holding Limited, respectively, follows from the documents. Through these legal entities, AFK Sistema owns an effective stake in Binnopharm Group in the amount of 75.3%, the newspaper said.
The press service of AFK Sistema confirmed to Interfax the fact of the redomication, but did not give informative comments on this matter. In February 2024, the corporation only said the following:
| | At the moment, there is a process of redomication, which was started some time ago. | |
Previously, Binnopharm Group LLC was 100% owned by Cyprus Ristango Holdings Limited. In turn, one of the shareholders of Ristango Holdings Limited is Sinocom Investments Limited, the agency recalls.
By February 2024, Binnopharm Group supplies its products to more than 10 countries, including,,, and Georgia Mongolia DPRK Yemen periodically. Afghanistan The share of export sales is about 10% of the total revenue structure of the holding. Mainly antibiotics are supplied to the CIS countries, but now the company will develop branded goods there, including the Maxilak synbiotic, the Neobutin antispasmodic agent and the venotonic Venarus. AFK[4]
2023
Summer internship by 160 students at Binnopharm Group production sites
One hundred and sixty students completed internships and practices in the summer of 2023 at five Binnopharm Group production sites in different regions of Russia. Of these, one hundred and forty people worked at the largest of the five factories of the company - PJSC Sintez in Kurgan. Read more here.
Agreement on the construction of a plant for the production of monoclonal antibodies to combat cancer
In June 2023, Binnopharm Group entered into a cooperation agreement with five Chinese strategic partners for a total amount of more than 3 billion rubles. Within the framework of the agreements reached, the Russian pharmaceutical company will build a plant for the production of monoclonal antibodies, including to combat cancer.
Binnopharm Group's strategic partners include major suppliers of equipment for pharmaceutical enterprises: Truking Technology Ltd. and Tofflon Science and Technology Group Co., Ltd. In 2023-2024, the company plans to modernize and expand the production capacity of factories and the R&D center. Equipment totaling over 1.2 billion rubles will allow launching lines for the production of sterile solutions using BFS technology, automatic filling lines for dispensing injection powders under aseptic conditions, and lines for the production of capsules.
Binnopharm Group's partner in the production of biological drugs will be the Chinese manufacturer Maxwell Biosciences. Cooperation involves the organization of the production of monoclonal antibodies to fight, including cancer. It is planned to completely localize - with the production of the substance - several drugs with their launch on the Russian market in 2025-2026. The size of investments will be more than 1.5 billion rubles.
| | Today, Russia and China are on a new round of development and strengthening of relations. Our countries have identified a strategic vector aimed, among other things, at significantly scaling up bilateral trade, improving logistics infrastructure, and strengthening cooperation in various fields. Pharmaceutical production is the basis of drug safety and an unconditional priority for both countries. It is very important to support the initiative to expand the Russian-Chinese partnership, which is demonstrated by leading Russian pharmaceutical manufacturers, - said the deputy head of the Ministry of Industry and Trade Ekaterina Prizhedeva.[5] | |
Plan to invest 5 billion rubles in development
Binnopharm Group plans to invest about 5 billion rubles in its own development in 2023, the company is implementing several projects to increase production capacity. This was announced on March 14, 2023 by the general director of Binnopharm Group Rustem Muratov.
| | We think that in 2023 we will invest about 5 billion rubles. There was a situation when there was a need for capacity growth, precisely in volume and quantity. We are implementing several projects of this format, "he said. | |
In addition, in the near future time the company plans to open a new - R&D center, work in this direction is at the final stage. Binnopharm Group is increasing the production of drugs, developing the export direction. In the first half of 2023, Binnopharm Group may open its own representative office in, China and the necessary documentation is being prepared for March 2023, the company's general director said. According to him, Binnopharm Group is technically ready for, IPO the timing depends on the interest of investors.
Internship of students of the Northern State Medical University at the factories "Alium"
Students Northern State Medical University undergo internships at the situated near Moscow pharmaceutical factories "" Alium(Obolensk) and "" Binnopharm(), Zelenograd which are part of the Binnopharm Group. They study the technology of production and quality management of medicines, which will provide an opportunity to get closer acquainted pharmaceutical industry with and gain skills in working on specialized equipment. Binnopharm Group announced this on February 16, 2023. More. here
Obtaining a GDP Certificate of Compliance
Binnopharm Group on January 12, 2023 announced that it has received an international certificate of compliance with the GDP (Good Distribution Practice) requirements, which certifies that the company has established and applies distribution good practice procedures for the wholesale, trade transportation and storage of medicines for medical and veterinary use.
Good Distribution Practice (GDP) is a quality assurance system for warehouse enterprises and wholesale bases in the field of circulation of medicines. The implementation of GDP rules ensures the availability of consistent quality management systems throughout the supply chain, including the supply of finished products to retail chains and medical institutions.
{{quote 'author=said Rustem Muratov, CEO of Binnopharm Group.|It is important that the company's activities fully comply with international standards. We believe that compliance with Good Distribution Practices is a requirement for any pharmaceutical company. GDP certification is becoming more and more significant in the framework of drug supplies both within Russia and abroad. In 2023, we plan to open a representative office in China, }}
2022 was the year of expansion for Binnopharm Group, the company's representative offices appeared in six countries CIS - the Republics, Belarus Moldova as well as,, and Azerbaijan. Armenia Uzbekistan Kazakhstan Binnopharm Group took first place in the sale of all pharmaceutical companies represented in the republic. Kyrgyzstan The company operates in all segments of the pharmaceutical market, producing products that are sold in 14 countries.
Binnopharm Group has a significant diversified portfolio represented in several sales channels, where expertise has already been developed in the field of international supplies to the CIS states, which will expand in other countries.
2022
Revenue and EBITDA growth by 21%, net revenue - by 12%
Pharmaceutical Binnopharm Group (part of the group) AFK Sistema on March 17, 2023 shared with Zdrav.Expert financial the results IFRS for (IFRS) for the full year ended December 31, 2022.
The company's revenue for the reporting period increased by 21%, exceeding 36 billion rubles. In turn, net revenue in 2022 increased by 12% year-on-year, mainly due to an increase in sales retail segment of the Russian Federation in and in foreign. countries Against the background of revenue growth, the indicator EBITDA increased year-on-year by 21% to 8.0 billion. As rubles a result of optimization of the product portfolio, control of administrative and commercial expenses, EBITDA margin increased by 2.3 pp year-on-year in 2022.
Фото: Максим Стулов / vedomosti.ru
The volume of sales in the retail segment increased by 34% year-on-year, which allowed to increase market share to 2.4%. At the same time, the sales growth rate was three times higher than the market growth rate, Binnopharm Group noted. The main growth drivers were sales of the drugs Venarus, Neobutin, Omeprazol, Kagocel, Kipferon.
According to the company, such results were achieved, first of all, thanks to the focus on promoting the largest brands Binnopharm Group - Angiorus, Diclofenak-AKOS, Neobutin, the turnover of each of them reached the level of 1.5 billion rubles. Binnopharm Group is actively developing its own brands through digital platforms, cooperation with pharmacy chains and television advertising. According to Mediascope, in March 2022, the company entered the top 15 advertisers on Russian television, taking second place among pharmaceutical companies at the end of the year.
Sales of Binnopharm Group products abroad increased by 23%, reaching a volume of 3 billion rubles. The company promotes its products countries in the presence both medical through representative teams and through advertizing campaigns. The growth in sales countries CIS in 2022 was influenced by the successful launch of the Maxilak synbiotic, the venotonic Venarus, the anti-inflammatory drug Dexonal, and the Neobutin antispasmodic to foreign markets. Sales of the antiviral drug Kagocel increased by more than 30% in 2022, amounting to 300 million rubles and 800 thousand packages.
According to the IQVIA analytical agency, Binnopharm Group is the leader among Russian companies supplying their products for export to neighboring countries. So, in 2022, the main drivers were the markets Uzbekistan where Kazakhstan Binnopharm Group is among the top 5 companies in terms of the number of sold packages of medicines - more than 38 million and 25 million packages, respectively. At the same time Kyrgyzstan , the company ranks first in the market at the end of the year not only in packages (more than 28 million), but also in monetary terms (more than 638 million rubles), its market share is more than 4%.
| | "Providing the population of the countries of presence with high-quality and affordable drugs is the main principle of our work. We have been growing faster than the market for several years in a row, and 2022 was no exception, - said Rustem Muratov, General Director of Binnopharm Group. "A successful promotion strategy, modernization of production sites, launch of new products, international expansion, research and development have created an effective platform demonstrating sustainable growth rates and high business profitability." | |
In turn, the company's net debt at the end of 2022 increased to 13.4 billion rubles against the background of a temporary increase in stocks of raw materials, auxiliary and packaging materials to ensure a smooth production process due to changes in supply chains in the new conditions, as well as from the effect of the M&A deal with Dr Reddy's. The net debt/OIBDA indicator is at the target level of 1.7x, Binnopharm Group added.
RUB 2.8 bln investment in advertising
Investments in advertising of drugs produced by Binnopharm Group in 2022 exceeded 2.8 billion rubles, while the bulk fell on television placement. The company announced this on April 7, 2023. The TV advertising budget is estimated at 2.2 billion rubles. The second priority area was placement on the Internet. Binnopharm Group spent more than 580 million rubles on it. The remaining funds were distributed between the press (9 million rubles), outdoor advertising (10 million rubles) and radio (22 million rubles).
| | The company's advertising strategy adapts to market changes. 2022 gave us the opportunity to actively engage in the development of products, the promotion of which was not previously a priority. The reduced advertising budgets of the farm and the departure of large players significantly influenced our strategy. We took advantage of the vacated niches, expanding the range of promoted drugs. This decision fully justified itself - at the end of the year, sales of Binnopharm Group drugs in the retail segment increased by 34%. By increasing investments in advertising projects on different sites, we received a noticeable increase in sales, said Rustem Muratov, CEO of Binnopharm Group.
| |
According to Binnopharm Group, the company was first included in the TOP-30 of Russian advertisers of the annual Sostav rating and became one of the three pharmaceutical companies on the list.
Amoxicillin sales growth to 2 million packages
The Russian pharmaceutical Binnopharm Group has increased sales antibiotic of Amoxicillin, which belongs to the same class of beta-lactam penicillin antibiotics (J01C) as Amoxiclav, which faced a shortage Moscow of pharmacies in December, by 2.5 times. The company announced this in December 2022. Almost 2 million packages of the drug were sold in 2022, sales revenue exceeded 170 million. rubles Also in 2022, the company launched the production of antibiotics from the carbapenem group - Imipenem-cilastatin and Doripenem.
| | The shortage of antibiotics may be due to difficulties in logistics, as well as the fact that in 2022 there was a significant increase in the cost of raw materials and materials, which pharmaceutical companies are obliged to take into account so that the production of drugs remains profitable. In general, the current situation can hardly be called critical, since in physical terms 70% of antibiotics sold in the Russian Federation are from domestic manufacturers. In the public procurement segment, the share of local products is even higher and reaches 90%, said Rustem Muratov, CEO of Binnopharm Group.
| |
In 2022, PJSC Sintez (part of Binnopharm Group) increased the production of beta-lactam antibiotics, including Sultasin - an increase of 33% year-on-year, Ampicillin - an increase of 69%, Ceftazidim - an increase of 24%, as well as Vancomycin - an increase of 33%.
First place among pharmaceutical companies of the Republic of Kyrgyzstan
Binnopharm Group announced on October 18, 2022 that it took first place in packaging among all pharmaceutical companies represented in the Republic of Kyrgyzstan in the first eight months of 2022. The market share in August 2022 was 13.8% according to the analytical agency IQVIA.
| | A large range of medicines manufactured at the production sites of Binnopharm Group is in demand and enjoys the confidence of the pharmaceutical market in Kyrgyzstan. We plan not only to retain, but also to increase our share due to the launch of new INNs and brands on the market, as well as blockbusters from the company's range of medicines. In October 2022, we are engaged in bringing the Maksilak line of synbiotics to the Kyrgyz market, the drugs of which occupy the third place in the targeted market in Russia by the end of August, and we expect that the line will be in demand in the new market. In 2022, we also took the antiviral drug Kagocel for promotion in the republic, it shows good results in its segment, said Rustem Muratov, General Director of Binnopharm Group. | |
At the end of 2021, Binnopharm Group registered six representative offices countries CIS in and began active work to promote Russian drugs in new markets for itself, and also strengthened the export direction as a whole.
| | Every new market is a big job. Everywhere there are their own rules that are interesting to study, to develop a strategy taking into account the peculiarities of the country. The CIS markets are promising in terms of marketing, and consumers have a positive attitude towards Russian products, - said Rustem Muratov. - Positive sales dynamics motivates our company to expand the portfolio of products presented in these countries. In Uzbekistan, Kazakhstan and Azerbaijan, we confidently enter the Top 10 pharmaceutical companies, which, I believe, is a great achievement, taking into account the fact that globally we took up the export direction only a year ago. | |
Replacement of equipment at the production site near Moscow
On May 31, 2022, the Binnopharm Group pharmaceutical company announced the implementation of an investment project at the Alium production site near Moscow, installing other equipment in the packaging workshop at the small-scale production of medicines. The installed blister machine works using special materials that provide a high degree of protection of the drug from oxidizing effects of oxygen, moisture, ultraviolet light and mechanical damage.
| | Our site was commissioned only three years ago - this is a production complex built in accordance with the best practices. At the same time, we continue to invest in the development of production and equip it with the latest equipment. Thanks to the blister machine installed at the small-scale production site, we can reduce the cost of purchasing tooling for packaging drugs produced in small batches several times, - commented Roman Kozin, director of the production department of the Binnopharm Group site near Moscow. - This blister machine is also equipped with a vision system that allows timely rejection of blisters that do not meet quality requirements. | |
The first drug released on this equipment was the drug Montelukast, which is used for maintenance therapy of stable asthma and is one of the five drugs prescribed for this diagnosis (about 8% of all prescriptions for this disease). In the first quarter of 2022, sales of Montelukast in Russia increased by 44% compared to the same period in 2021. The drug is on prescription.
The start of the creation of a pharmaceutical warehouse complex in Kurgan for 2 billion rubles
On February 4, 2022, the pharmaceutical company Binnopharm Group (part of the AFK Sistema Group) announced to Zdrav.Expert that it had begun designing a modern pharmaceutical warehouse complex at the Sintez plant in Kurgan, where the stock of raw materials, materials, as well as finished products will be concentrated. Investments in the project will amount to about 2 billion rubles. Read more here.
The start of supplies of the drug from coronavirus "Favipiravir"
On February 2, 2022, the Binnopharm Group pharmaceutical company announced that it had delivered the first batch of Favipiravir to the Russian market, which was recommended by the Ministry of Health in protocols for the treatment of COVID-19. Marketing authorization for the drug was received in September 2021. Read more here.
2021
Revenue growth by 19.3% to 25.5 billion rubles
On April 25, 2022, the Russian manufacturing pharmaceutical company Binnopharm Group (part of Sistema Group of Companies) shared with Zdrav.Expert its audited consolidated financial results prepared in accordance with IFRS for the full year ended December 31, 2021. Revenue for the 12 months of 2021 increased by 19.3% to 25.5 billion rubles due to sales growth in the retail, hospital and export segments of the pharmaceutical market.
As explained in the company, the financial results are presented according to the proforma of the results of Binnopharm Group, obtained through the technical consolidation of the financial results of Alium JSC (with subsidiaries, including Binnopharm JSC) and Synthesis PJSC (with a subsidiary of Biocom JSC).
Sales growth in the hospital segment for the 12 months of 2021 amounted to 27% year-on-year. The company increased sales in the retail segment by 20% over the year, which is three times the growth rate of the retail segment of the market for 2021. The key growth drivers here were sales of Binnopharm Group products aimed at improving the quality of life of consumers - Angiorus venotonic, Maxilac synbiotic, Ophlomelid antimicrobial and anti-inflammatory ointment, Neobutin antispasmodic and others.
Binnopharm Group also actively developed its export direction, increasing sales by 15% year-on-year. At the end of 2021, the company announced the beginning of international expansion and the opening of official representative offices countries CIS in Kazakhstan-,,,, and Belarus Azerbaijan. To Moldova Armenia This Uzbekistan allows Binnopharm Group to create a system for promoting the company's products in foreign countries and strengthen the presence of these markets.
| | "In 2021, Binnopharm Group increased OIBDA by 48.7% to 8.1 billion rubles. The significant growth of OIBDA is associated with revenue growth, serious optimization of administrative and commercial expenses and harmonization of the product portfolio, "said Rustem Muratov, General Director of Binnopharm Group. | |
Modernization of the production of drugs in the form of sachets for 100 million rubles
The pharmaceutical company Binnopharm Group (part of the AFK Sistema Group) on December 14, 2021 announced that it had modernized the site for the production of sachets at the Alium plant in the village of Obolensk, Moscow Region, increasing its capacity to 50 million sachets per year. The company plans to gradually transfer the production of all its sachets to the Alium plant. Investments in the project amounted to 100 million rubles. Read more here.
AFK Sistema increased its stake in Binnopharm Group to 75.3%
On December 14, 2021, AFK Sistema announced an increase to 75.3% of its effective stake in the Binnopharm Group holding, which, among other things, is engaged in the production of the Sputnik V coronavirus vaccine.
AFK Sistema exercised its right to purchase shares of Sinocom Investments Limited from VTB in the amount of 9.06 billion rubles. What effective share VTB sold is not indicated in the message of AFK Sistema. Sinocom Investments owns shares in Ristango Holding Limited, which in turn owns 100% of Binnopharm Group's share capital. The transaction was attended by a subsidiary of AFK Sistema, Sistema Telecom Assets LLC, and VTB Bank (Europe) SE. At the same time, VTB Capital, through the structure of Nevsky Property Investments, remains the owner of 11.2% in Ristango. VTB Group at one time became a co-owner in Sinocom as a result of its participation in financing the consolidation of a number of pharmaceutical assets and the creation of the Binnopharm Group holding.
A source RBC close to AFK Sistema noted that the corporation bought out the bank's share at the price recorded back in 2019. According to him, now the asset is 2.5-3 times more expensive.
| | The corporation plans to continue to increase its presence in the pharmaceutical sector. We are confident in the future prospects of Binnopharm Group, which today demonstrates high business growth and profitability. We believe that the company can become one of the main drivers of increasing the value of the portfolio of assets of AFK Sistema, - the words of AFK Sistema President Vladimir Chirakhov are quoted in the message. | |
By December 2021, other co-owners of Binnopharm Group remain members of a consortium of investors represented by the Russian Direct Investment Fund (RDIF), the Russian-Chinese Investment Fund, as well as Middle Eastern funds.[6]
Registration of representative office in Kazakhstan
On December 3, 2021, Binnopharm Group registered an official representative office Kazakhstan in and in the next month will open offices in 5 more - countries CIS the Republic,,, and Belarus Azerbaijan. To Moldova Armenia This Uzbekistan will allow in 2024 to double the revenue from export sales and will be the first step in building the infrastructure of an international company.
| | This is an important historical moment in the development of the Binnopharm Group. With the opening of foreign missions, we will have our own local promotion system, which will make it possible to develop faster in these countries. We expect that in 2024 our export sales will double, "said Rustem Muratov, CEO of Binnopharm Group. | |
With the opening of representative offices, the company begins to promote branded products - the Maxilak synbiotic, the Neobutin antispasmodic agent, the venotonic Venarus and others.
| | The population of the CIS countries, if Ukraine is excluded, is about half of the population of the Russian Federation. At the same time, for 8 months of 2021, the Russian pharmaceutical market grew by 4.7% in monetary terms, and the market, for example, Uzbekistan - by 68%. The growth is primarily associated with an increase in the well-being of the population of countries and an increase in consumption in physical terms, - said Rustem Muratov. - To promote on the ground, we have focused on several branded drugs and plan to increase sales volumes on them abroad. | |
The opening of the first representative offices abroad is the beginning of the international expansion of Binnopharm Group. "We are starting to build the infrastructure of Binnopharm Group as an international company. Having set up processes and developed expertise to promote drugs in different countries, we plan to expand our international presence and eventually enter the markets of other countries, we are now considering the countries of the Middle East and Southeast Asia, "commented Rustem Muratov.
Agreement with Sartorius to organize the production of biotechnological products
On November 17, 2021, the pharmaceutical company Binnopharm Group and one of the manufacturers of equipment for the biopharmaceutical industry, the German company Sartorius, signed a strategic partnership agreement, under which it is planned to implement projects to organize the production of biotechnological drugs, including vaccines against COVID-19.
| | Two years ago, Sartorius became our technological partner: we together began to develop a platform on which any products based on adenovirus can be produced, including the Sputnik V vaccine. This platform is a comprehensive technological solution: equipment, guidelines, calculations on the necessary consumables and other components, - commented Rustem Muratov, General Director of Binnopharm Group. - The development and production of biotechnological drugs is one of our key areas, which we intend to develop, among other things, through a strategic partnership with Sartorius. | |
| | The created technological platform for the production of vector drugs is universal and therefore has great potential for transfer, including to foreign countries, Irina Volkova, General Director of Sartorius in Russia, noted that we intend to develop a partnership with Binnopharm Group not only in the field of biotechnology, but also in other promising areas - such as gene therapy, cell drugs, products based on viral vectors. | |
Binnopharm Group and Sartorius began to actively cooperate in 2019 as part of a project to scale the production of the Sputnik V vaccine. At that time, only two companies in the world - Sartorius and General Electric Healthcare - produced equipment that is used in the production of vector vaccines. The partnership with Sartorius allowed Binnopharm Group to launch industrial production of the vaccine in a record time at that time - in 4 months.
Creation of an R&D center in the Moscow region for 2.5 billion rubles
On September 9, 2021 pharmaceutical , Binnopharm Group announced Zdrav.Expert the creation of R&D a center Krasnogorsk in the area that Moscow region will unite the research divisions of all the company's enterprises. The project involves the creation of a center for the pharmaceutical development of chemical synthesis drugs and a center for the development of biotechnological drugs. Investments will amount to 2.5 billion. rubles
Источник фото: RBC
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |